Company news
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) news
Every Xeris Biopharma Holdings, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
medmix' Drug Delivery ("Haselmeier") to Support the Development of Xeris Pharmaceuticals' XP-8121 with D-Flex(TM) Pen Injector
September 10, 2026
Medmix : rsquo; Drug Delivery (“Haselmeier”) to support the development of Xeris Pharmaceuticals’ XP-8121 with D-Flex™ pen injector
September 10, 2026
Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxi...
September 9, 2026
Xeris Announces Details for XP-8121 Program Overview Webinar
August 26, 2026
Xeris Biopharma : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)
August 6, 2026
Xeris Biopharma Reports Second Quarter 2026 Financial Results
August 6, 2026
Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026
July 23, 2026
CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
July 2, 2026
Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
July 2, 2026
Xeris Announces Updates to Its Board of Directors
June 30, 2026
Xeris Biopharma Announces Private Exchange of Convertible Notes
June 11, 2026
Xeris Biopharma Reports First Quarter 2026 Financial Results
May 7, 2026
Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026
April 23, 2026
Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance
March 2, 2026
Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit
February 26, 2026
Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026
February 17, 2026
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue
January 8, 2026
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 2, 2026
Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application
December 1, 2025
Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025
November 6, 2025
Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025
October 23, 2025
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 3, 2025
Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®
August 25, 2025
Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance
August 7, 2025
Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025
July 31, 2025
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day
June 3, 2025
Xeris Announces Details for Analyst & Investor Day
May 20, 2025
Xeris Biopharma Reports Record First Quarter 2025 Financial Results
May 8, 2025
Xeris Biopharma Reports Record First Quarter 2025 Financial Results
May 8, 2025
Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025
May 1, 2025
Xeris Announces Changes to Its Board of Directors
March 28, 2025
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid
March 17, 2025
Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance
March 6, 2025
Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025
February 27, 2025
Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer
February 24, 2025
Xeris to Participate in Upcoming Investor Conferences
February 5, 2025
The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education...
January 21, 2025
Xeris Expects to Exceed Full-Year 2024 Financial Guidance
January 10, 2025
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 6, 2025
Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference
November 26, 2024
Xeris Biopharma Reports Third Quarter 2024 Financial Results
November 8, 2024
Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024
October 31, 2024
Xeris Biopharma Reports Second Quarter 2024 Financial Results
August 8, 2024
Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024
July 25, 2024
Xeris Biopharma Announces CEO Succession Plan
July 8, 2024
Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024
June 3, 2024
Xeris to Participate in the Jefferies Global Healthcare Conference
May 30, 2024
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC)...
May 30, 2024
Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events
May 9, 2024
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics
May 6, 2024